Published in PLoS One on April 20, 2010
Vitamin D Supplementation in Women With DCIS and/or LCIS | NCT02936999
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol Cell Biol (2011) 1.52
Autophagy in stem cells. Autophagy (2013) 1.43
Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene (2013) 1.41
Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol (2010) 1.23
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat (2011) 1.18
Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem (2012) 1.17
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One (2011) 1.06
Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One (2013) 1.04
One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One (2011) 1.03
Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK. Oncogene (2012) 1.03
Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions. J Biol Chem (2013) 1.02
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Targeting autophagy in breast cancer. World J Clin Oncol (2014) 0.99
Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model. Mol Cell Pharmacol (2012) 0.98
Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure. BMC Cancer (2015) 0.96
The multifaceted roles of autophagy in tumors-implications for breast cancer. J Mammary Gland Biol Neoplasia (2011) 0.96
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res (2014) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion. Mol Cancer Res (2015) 0.93
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 0.93
Mechanisms of autophagy and apoptosis: Recent developments in breast cancer cells. World J Biol Chem (2011) 0.87
Roles of microRNA-140 in stem cell-associated early stage breast cancer. World J Stem Cells (2014) 0.87
Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther (2014) 0.85
Autophagy in cancer metastasis. Oncogene (2016) 0.81
Stress signaling and the shaping of the mammary tissue in development and cancer. Oncogene (2014) 0.79
Attacking breast cancer at the preinvasion stage by targeting autophagy. Womens Health (Lond Engl) (2013) 0.78
Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett (2013) 0.78
Characterization of the CD49f+/CD44+/CD24- single-cell derived stem cell population in basal-like DCIS cells. Oncotarget (2016) 0.77
Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep (2015) 0.77
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ. Int J Surg Oncol (2012) 0.76
Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. Oncotarget (2016) 0.75
High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. J Pathol Clin Res (2014) 0.75
Non-enzymatic, serum-free tissue culture of pre-invasive breast lesions for spontaneous generation of mammospheres. J Vis Exp (2014) 0.75
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Effect of increased extracellular ca on microvesicle production and tumor spheroid formation. Cancer Microenviron (2010) 0.75
The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Semin Oncol (2015) 0.75
Glucose restriction combined with autophagy inhibition and chemotherapy in HCT 116 spheroids decreases cell clonogenicity and viability regulated by tumor suppressor genes. J Proteome Res (2017) 0.75
Global variation in copy number in the human genome. Nature (2006) 57.50
Large-scale copy number polymorphism in the human genome. Science (2004) 34.64
The impact of next-generation sequencing technology on genetics. Trends Genet (2008) 21.07
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res (2008) 8.01
Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol (2005) 7.11
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 5.84
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Autophagy and cell death. Curr Top Dev Biol (2007) 3.44
Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell (2007) 3.37
Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol Cell Biol (2001) 3.31
Autophagy and human disease. Cell Cycle (2007) 3.22
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ (2008) 2.84
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Does autophagy have a license to kill mammalian cells? Cell Death Differ (2008) 2.30
Autophagy and cancer therapy. Autophagy (2006) 2.13
Autophagy: an emerging target for cancer therapy. Autophagy (2008) 1.94
Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia (2005) 1.92
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One (2009) 1.91
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
STAGA recruits Mediator to the MYC oncoprotein to stimulate transcription and cell proliferation. Mol Cell Biol (2007) 1.78
Tumor suppression by autophagy through the management of metabolic stress. Autophagy (2008) 1.71
Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev (2005) 1.59
Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer (2006) 1.56
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy (2009) 1.50
Induction of macroautophagy by exogenously introduced calcium. Autophagy (2008) 1.48
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Extracellular matrix regulation of autophagy. Curr Opin Cell Biol (2008) 1.44
Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res (2009) 1.41
Biochemical isolation and characterization of the tubulovesicular LC3-positive autophagosomal compartment. J Biol Chem (2009) 1.41
Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer (2005) 1.38
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res (2008) 1.38
Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res (2007) 1.18
Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. Mol Cell Biol (2008) 1.12
Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res (2008) 1.07
Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. Ann Surg Oncol (2007) 1.03
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer (2003) 1.00
Human breast epithelial stem cells and their regulation. J Pathol (2006) 1.00
Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett (1995) 0.98
Cancer: whispering sweet somethings. Nature (2008) 0.88
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Laser-capture microdissection. Nat Protoc (2006) 3.80
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst (2005) 2.63
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol (2009) 2.54
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol (2003) 2.21
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol (2004) 1.81
Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol (2011) 1.80
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol (2010) 1.78
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
Proteomics of human breast ductal carcinoma in situ. Cancer Res (2002) 1.62
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Anoikis: cancer and the homeless cell. Nature (2004) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest (2006) 1.52
Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci U S A (2011) 1.52
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 1.50
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Laser capture microdissection technology. Expert Rev Mol Diagn (2007) 1.43
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic (2002) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One (2007) 1.34
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 1.31
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res (2005) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Cancer: Out of air is not out of action. Nature (2003) 1.30
Analysis of mass spectral serum profiles for biomarker selection. Bioinformatics (2005) 1.30
Ovarian cancer detection by logical analysis of proteomic data. Proteomics (2004) 1.28
Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem (2006) 1.28
Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia (2002) 1.26
Biomarker amplification by serum carrier protein binding. Dis Markers (2004) 1.26
An initial characterization of the serum phosphoproteome. J Proteome Res (2009) 1.26
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) (2005) 1.25